Key facts
- This page summarizes David A. Santos's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jun 2026, 18:02.
David A. Santos - 01 Jun 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)
- Reporting relationship
- EVP, Chief Commercial Officer
- Issuer ticker
- RIGL
- Reported as of
- 01 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jun 2026, 18:02:55 UTC
- Prior SEC filing
- 19 Feb 2026
- Next SEC filing
- 22 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Raymond Furey (Attorney-in-Fact)
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David A. Santos filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 03 Jun 2026.
Change
- Previous filing in this sequence was filed on 19 Feb 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001820066
Primary reporting owner
Santos David A
- Relationship
- EVP, Chief Commercial Officer
- Address
- RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO
- Signature
- /s/ Raymond Furey (Attorney-in-Fact)
- Signature date
- 03 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RIGL
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -874
- Change %
- -1.4%
- Price
- $29.86*
- Shares after
- 61,996
- Date
- 01 Jun 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.